Your browser doesn't support javascript.
loading
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier, Patricia; Italiano, Antoine; Piperno-Neumann, Sophie; Chevreau, Christine; Penel, Nicolas; Firmin, Nelly; Boudou-Rouquette, Pascaline; Bertucci, François; Balleyguier, Corinne; Lebrun-Ly, Valérie; Ray-Coquard, Isabelle; Kalbacher, Elsa; Bardet, Aurélie; Bompas, Emmanuelle; Collard, Olivier; Isambert, Nicolas; Guillemet, Cécile; Rios, Maria; Archambaud, Baptiste; Duffaud, Florence.
Affiliation
  • Pautier P; Department of Medical Oncology, University Paris-Saclay, Gustave-Roussy, Villejuif, France. Electronic address: patricia.pautier@gustaveroussy.fr.
  • Italiano A; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
  • Piperno-Neumann S; Department of Medical Oncology, Institut Curie, Paris Sciences et Lettres Research University, Paris, France.
  • Chevreau C; Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Penel N; Lille University and Department of Medical Oncology, Centre Oscar-Lambret, Lille, France.
  • Firmin N; Department of Medical Oncology, Institut du Cancer de Montpellier and Montpellier University, Montpellier, France.
  • Boudou-Rouquette P; Department of Medical Oncology, Hôpital Cochin, Paris, France.
  • Bertucci F; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
  • Balleyguier C; Department of Radiology, University Paris-Saclay, Gustave-Roussy, Villejuif, France.
  • Lebrun-Ly V; Department of Medical Oncology, Centre Hospitalo-Universitaire Dupuytren, Limoges, France.
  • Ray-Coquard I; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude-Bernard, Lyon, France.
  • Kalbacher E; Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Bardet A; Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Ligue Contre le Cancer, Villejuif, France.
  • Bompas E; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers-Nantes, France.
  • Collard O; Department of Medical Oncology, Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, France.
  • Isambert N; Department of Medical Oncology, Centre Georges-François-Leclerc, Dijon, France.
  • Guillemet C; Department of Medical Oncology, Centre Henri-Becquerel, Rouen, France.
  • Rios M; Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.
  • Archambaud B; Bureau of Biostatistics and Epidemiology, University Paris-Saclay, Gustave-Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Ligue Contre le Cancer, Villejuif, France.
  • Duffaud F; Department of Medical Oncology, La Timone University Hospital, Marseille, France.
Lancet Oncol ; 23(8): 1044-1054, 2022 08.
Article in En | MEDLINE | ID: mdl-35835135
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leiomyosarcoma Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leiomyosarcoma Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: United kingdom